Pharming reports positive Phase II results for leniolisib in rare immune disorders
Pharming Group (NASDAQ:PHAR) announced positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation caused by PI3Kδ signaling abnormalities.










